MindWalk, a biotechnology company specializing in artificial intelligence, showcased its ReefIQ platform for AI-driven drug discovery at AMD's Advancing AI event on July 24, 2026. The demonstration highlighted how ReefIQ leverages AMD's computing technology to accelerate the identification of potential drug candidates.
ReefIQ uses advanced machine learning algorithms to analyze molecular structures and predict their efficacy, potentially reducing the time and cost of early-stage drug development. The platform is designed to integrate with existing pharmaceutical workflows.
AMD's Advancing AI event, held in San Francisco, focused on the latest innovations in high-performance computing and AI. MindWalk's participation underscores the growing role of AI in life sciences, particularly in speeding up the discovery of new treatments.
No specific drug candidates or partnerships were announced during the presentation. MindWalk continues to develop ReefIQ for broader industry adoption.
